Clinical Trial

Study of GS-2426 in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in participants with MTAP-deleted advanced solid tumors and to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase II dose (RP2D).
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-25
Trial Details
NCT Number NCT07601243
Lead Sponsor Gilead Sciences
Conditions Advanced Solid Tumors
Enrollment 174 participants
Start Date 2026-06-02
Primary Completion 2029-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-03